When combined with clinical biomarkers (fasting glucose, insulin levels, lipid profile) and metabolic history, genetic insights from the Precision Peptide Genetic Test can help your provider personalize whether branded or compounded formulations align best with your individual treatment pathway
Lack of Long-Term Safety Data BPC-157s long-term safety is unknown
In the SELECT trial that included over 17,000 patients with obesity and established CV disease, but without diabetes, weekly s.c
GLP-1 Agonists Market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032
For smaller doses, 0.5 mL (50 unit) or 0.3 mL (30 unit) syringes provide better precision
Over the last few years, a dramatic surge in patient utilization has been observed across advanced domestic sports medicine networks